Fullife Healthcare's Differentiated 'innogenerics' are Bolstering the In-licensing Pipeline of Indian Pharma Companies

Monday, January 29, 2018 General News
Email Print This Page Comment bookmark
Font : A-A+

MUMBAI, January 29, 2018 /PRNewswire/ --

The Company has entered into multiple arrangements

in which it is out-licensing its molecules to established Indian pharma innovators and providing them access to better know-how through its portfolio of advanced 'innogenerics'

Mumbai-based Fullife Healthcare

Private Limited's subsidiary Fullife Connect (FLC) has been filling up the 'in-licensing pipeline' of Indian pharmaceutical companies by out-licensing its original molecules in novel delivery formats. FLC has signed in-licensing deals with leading Indian pharmaceutical companies such as Cipla, Cadila Healthcare, Adroit Biomed, Zydus, Macleods Pharmaceuticals, Samarth Life Sciences and Indoco Remedies, among others.

FLC's objective behind these in-licensing tie-ups is to identify ideas and updated technologies for chronic conditions and supply them to the Indian masses. "Our out-licensing effort is aimed at enabling easy accessibility of high quality, high innovation and safe products to the masses in a 'chronic conditions' country, such as India," stated Varun Khanna, Director at Fullife Healthcare . "We make them into unique formulations with a key focus on quality and commercial feasibility," Mr. Khanna added.

In this area of business, FLC's pipeline is focussed on out-licensing of nutritional and pharmaceutical products in key therapeutic areas critical to India. Orthopaedic, critical care, gynaecology, and cachexia, amongst others, are the key areas of focus for FLC, considering the high unmet demands in these segments.

Some key products supplied by FLC are: Pool, a unique ingredient developed for Cachexia aimed at helping cancer patients increase their body mass; and Bonolive, a unique olive extract that assists in pain management and also in managing the root cause of osteoporosis. FLC is currently on the look-out for partners to market this product. A popular product for weight loss and a new anti-oxidant are some other products manufactured by Fullife.

Providing New Generation Delivery Format Fullife supplies new-generation drugs, formulations and novel delivery format vehicles as per international standards and recognition. It manufactures these at its state-of-the-art effervescent facility equipped with the latest infrastructure and led by qualified scientists. While its nutritional products rely on novel discovery, its range of pharmaceutical products is innovative in their delivery format, and hence are termed as 'innogenerics'.

The opportunity for out-licensing is huge in India, considering that the nation is fast becoming product and quality conscious. By entering into strategic partnerships with FLC, the pharmaceutical companies are enabling these innovative products make a foray into new market segments. "In-licensing provides exclusivity and a unique value proposition to pharmaceutical companies in India, which are facing pricing pressure and competition in the local market for branded generics," said Snehal Shah, CEO, Fullife Healthcare.

Enhancing User-Friendly Experience Fullife's effervescent products offer the advantage of rapid bio-availability and a better user-friendly patient experience. The novel delivery formats through which they are supplied make the effervescent products fun, healthy and complaint. These are 'effergised' by dosages with superior taste and ease of use, thereby enabling enhanced medical patient compliance in India. "We effergise products, which have high dosage requirement and are difficult to consume, by combining multiple dosages into a single sachet," asserted Mr. Shah.

A Growing Business The company has projected its B2B segment of out-licensing to grow 4-fold by 2020, from its current revenue of Rs 15 crore. "We are leveraging our B2B segment to strengthen our therapy portfolio with a range of innovative offerings for managing several diseases. FLC develops and innovates exclusive nutritional and pharmaceutical products with a patented life, takes them through clinical trials, and finally, forges out-licensing arrangements with specialty pharmaceutical companies," stated Mr. Khanna.

Fullife is an innovative product player in the Indian and global markets. The company is capitalising on its specialised and proprietary effervescence technology that it acquired from Europe. The company, which commenced its Indian operations in 2010, specialises in the manufacturing of a range of differentiated effervescent products with a special focus on 'preventive healthcare and active living' segment.

A Tectonic Market Shift From bolstering indigenous research and lapping up late clinical stage drugs or new brands, there is a seismic market shift in India, which enables the supply of generics to the daunting world of innovative or differentiated brands. Buffeted by price controls and local competition in India for branded generics, and due to price erosion and tougher scrutiny in United States, Indian pharmaceutical companies are gradually turning their attention to in-licensing of molecules under development.

The growing competitive intensity in base business is pushing Indian companies to pursue new product opportunities that allow them incremental growth. Besides developing and marketing these products, the arrangement also helps the pharmaceutical players reap the benefits of fewer risks, newer capabilities and a fresh revenue stream. The trend of in-licensing by Indian pharmaceutical companies is fast gaining significance from a strategy view point and is seen becoming a key growth driver for the pharmaceutical companies.

About Fullife Healthcare Private Limited: 

Mumbai-based Fullife Healthcare Private Limited is committed to revolutionise health management through trending innovation, global alliances and an asset-light, smart-manufacturing business model. The company brings a fresh perspective to healthcare management, in which 'Prevention is The New Cure'. Fullife's growing portfolio of clinically approved, branded, pharmaceutical, Nutraceutical and Cosmeceutical OTC products - are available in 22 countries across the globe, including India. Fullife's flagship brand 'FAST&UP' has gained wide acceptance by the rapidly growing 'up-market' consumer segment, that comprises discerning users who believe in an 'Active Living' lifestyle. For more information, visit http://www.fullife.co.in.

For More Information, Please Contact: Fullife Healthcare Private Limited Varun Khanna +91-98200-10632 varun@fullife.co.in Dickenson Financial PR Mehul Mehta +91-98202-80325 mehul.mehta@dickensonir.com

Advertisement


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store